AMLX — Amylyx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1658551 ·
Last close
$14.59
Market Cap
$1.62B
52W High
$18.60
52W Low
$12.44
ADV30
1,231,127
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -43,779,000 | -41,284,000 | 293,603,000 | 229,136,000 | 20,442,000 |
| Dec 2025 | 0 | 0 | -36,605,000 | -32,999,000 | 332,645,000 | 226,651,000 | 27,386,000 |
| Sep 2025 | 0 | 0 | -36,027,000 | -34,386,000 | 362,741,000 | 225,178,000 | 30,745,000 |
| Jun 2025 | 0 | 0 | -42,857,000 | -41,443,000 | 194,598,000 | 58,085,000 | 26,721,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,343,000
Investing CF
$14,039,000
Financing CF
$257,029,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.55
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-751,427,000
Inventory
$0
Receivables
$88,000
ST Investments
$90,328,000
EBIT TTM
$-153,292,000
Pretax Income TTM
$-144,689,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -153,291,000 | -144,735,000 | 332,645,000 | 27,386,000 | — | -123,343,000 |
| Dec 2024 | 87,371,000 | -255,677,000 | -301,743,000 | 193,634,000 | 28,869,000 | — | -167,647,000 |
| Dec 2023 | 380,786,000 | 38,802,000 | 49,271,000 | 517,454,000 | 84,022,000 | — | 11,919,000 |
| Dec 2022 | 22,230,000 | -201,341,000 | -198,375,000 | 391,453,000 | 50,846,000 | — | -179,871,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.27
Max Pain — expiry 2026-06-18
max pain strike: $14.00 · spot: $15.19 · call oi: 3,419 · put oi: 1,924
Expected Move to 2026-06-18:
±$3.62
(23.83%) —
implied range
$11.57 –
$18.81
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | $1.62B | $35.92 | — |
| SEPN | Septerna, Inc. | $1.62B | $35.95 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.62B | $18.25 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.62B | $15.31 | — |
| CMPS | COMPASS Pathways plc | $1.63B | $12.08 | — |
News headlines (Yahoo Finance, 1h cache)
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
2026-06-10 22:12 · Yahoo
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
2026-06-08 13:00 · Yahoo
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound
2026-06-01 15:11 · Yahoo
Amylyx Stock: Why the Full Pipeline Story Matters
2026-05-24 12:50 · Yahoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress
2026-05-20 20:42 · Yahoo
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 17:37 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
2026-05-15 16:11 · Yahoo
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
2026-05-14 05:05 · Yahoo
Amylyx (AMLX) Q1 2026 Earnings Transcript
2026-05-08 15:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.